摘要
Objective： To analyze the clinical evaluation of Parkinson＇s disease （PD） patients receiving integrated Chinese and Western medicine therapy. Methods： One hundred and twenty patients were enrolled and randomly allocated to a control group or treatment group. Patients in the two groups received placebo and Bushen Huoxue Granule （补肾活血颗粒, BHG）, respectively. Both groups received baseline levodopa and benserazide （Madopar）. The effects of treatment were assessed monthly during the 9-month treatment. Means of evaluation included Unified PD Rating Scale （UPDRS） scores （Ⅱ and Ⅲ）, sleep scale score, 10 m turn back test （getting up time, 10 m × 2 times, and turning time）, timing motor test （TMT）-Ieft and TMT-right, which were treated as the dependent variables; and age, sex, duration of PD, Hoehn and Yahr （H-Y） stage and Madopar dosage of admitted PD patients were as the independent variables. Multiple linear regression was used to analyze these factors. Results： H-Y stage significantly affected UPDRSⅡ score, UPDRS Ⅲ score, and getting up time （P〈0.01）. Madopar dosage and H-Y stage significantly affected the 10 m × 2 times （P〈0.05 or P〈0.01）. Madopar dosage significantly affected the sleep scale score （P〈0.05）. There were also significant correlations between age and TMT-left or TMT-right （P〈0.01）, and duration of PD and TMT-right （P〈0.05）. Conclusions： The six assessed means of clinical evaluation （including UPDRS Ⅱ and UPDRS Ⅲ scores, sleep scale score, getting up time, 10 m × 2 times, and turning time） are sensitive indexes in all PD patients. H-Y stage and Madopar dosage are the major factors influencing means of clinical assessment of PD treatment.
Objective： To analyze the clinical evaluation of Parkinson＇s disease （PD） patients receiving integrated Chinese and Western medicine therapy. Methods： One hundred and twenty patients were enrolled and randomly allocated to a control group or treatment group. Patients in the two groups received placebo and Bushen Huoxue Granule （补肾活血颗粒, BHG）, respectively. Both groups received baseline levodopa and benserazide （Madopar）. The effects of treatment were assessed monthly during the 9-month treatment. Means of evaluation included Unified PD Rating Scale （UPDRS） scores （Ⅱ and Ⅲ）, sleep scale score, 10 m turn back test （getting up time, 10 m × 2 times, and turning time）, timing motor test （TMT）-Ieft and TMT-right, which were treated as the dependent variables; and age, sex, duration of PD, Hoehn and Yahr （H-Y） stage and Madopar dosage of admitted PD patients were as the independent variables. Multiple linear regression was used to analyze these factors. Results： H-Y stage significantly affected UPDRSⅡ score, UPDRS Ⅲ score, and getting up time （P〈0.01）. Madopar dosage and H-Y stage significantly affected the 10 m × 2 times （P〈0.05 or P〈0.01）. Madopar dosage significantly affected the sleep scale score （P〈0.05）. There were also significant correlations between age and TMT-left or TMT-right （P〈0.01）, and duration of PD and TMT-right （P〈0.05）. Conclusions： The six assessed means of clinical evaluation （including UPDRS Ⅱ and UPDRS Ⅲ scores, sleep scale score, getting up time, 10 m × 2 times, and turning time） are sensitive indexes in all PD patients. H-Y stage and Madopar dosage are the major factors influencing means of clinical assessment of PD treatment.
基金
Supported by the National Ministry of Science and Technology "Eleventh Five-Year" Project of China(No.2006BA104A11)
